⌘K
t
| Date | 26 Mar 2024 |
| Time | 07:00:17 |
| Category | Miscellaneous |
| ID | 1931I |
genedrive plc
("genedrive" or the "Company")
Investor presentation
As previously announced, genedrive plc (AIM: GDR), the point of care pharmacogenetic testing company, will release its interim results for the six months ended 31 December 2023 on 28 March 2024.
The Company will provide a live presentation to accompany the results, presented by Chief Executive Officer James Cheek, Chief Financial Officer Russ Shaw and Chief Scientific Officer Gino Miele, on Friday, 5 April 2024 at 10.00am.
The presentation will be hosted through the digital platform Investor Meet Company. Investors can sign up to Investor Meet Company for free and add to meet genedrive plc via the following link: https://www.investormeetcompany.com/genedrive-plc/register-investor
For further details please contact:
|
genedrive plc |
+44 (0)161 989 0245 |
|
James Cheek: CEO / Russ Shaw: CFO |
|
|
|
|
|
Peel Hunt LLP (Nominated Adviser and Broker) |
+44 (0)20 7418 8900 |
|
James Steel / Patrick Birkholm |
|
|
|
|
|
Walbrook PR Ltd (Media & Investor Relations) |
+44 (0)20 7933 8780 or genedrive@walbrookpr.com |
|
Anna Dunphy |
+44 (0)7876 741 001 |
About genedrive plc (http://www.genedriveplc.com)
genedrive plc is a pharmacogenetic testing company developing and commercialising a low cost, rapid, versatile, simple to use and robust point of need pharmacogenetic platform for the diagnosis of genetic variations. This helps clinicians to quickly access key genetic information that will help them make the right choices over the right medicine or dosage to use for an effective treatment. Based in the UK, the Company is at the forefront of work on Point of Care pharmacogenetics. Pharmacogenetics looks at how your genetics impacts a medicines ability to work for you. Therefore, by using pharmacogenetics, medicines can be made safer and more effective. The Company has launched its flagship product, the Genedrive® MT-RNR1 ID Kit, which is a single-use disposable cartridge which circumvents the requirement for cold chain logistics by providing temperature stable reagent test kits for use on their proprietary test platform. This test allows clinicians to make a decision on antibiotic use within 26 minutes, ensuring vital care is delivered with no negative impact on the patient pathway.
The Company has a clear commercial strategy focused on accelerating growth through maximising in-market sales, geographic and portfolio expansion and strategic M&A, and operates out of its facilities in Manchester.